Señales en vivo de 4157.TWO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 22:23):

Stats
Volumen de hoy	295 017
Volumen promedio	2.59M
Capitalización de mercado	10.77B
EPS	TWD0 ( 2024-03-20 )
Próxima fecha de ganancias	( TWD0 ) 2024-05-09
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	78.95
ATR14	TWD0.0120 (0.08%)

Volumen Correlación

Largo: -0.12 (neutral)

Corto: -0.62 (weak negative)

Signal:(32.728) Neutral

TaiGen Biopharmaceuticals Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TaiGen Biopharmaceuticals Correlación - Moneda/Commodity

-0.83
( strong negative )

-0.82
( strong negative )

0.00
( neutral )

-0.64
( weak negative )

0.08
( neutral )

0.81
( strong )

TaiGen Biopharmaceuticals Finanzas

Annual	2023
Ingresos:	TWD123.13M
Beneficio Bruto:	TWD84.08M (68.28 %)
EPS:	TWD0.190

FY	2023
Ingresos:	TWD123.13M
Beneficio Bruto:	TWD84.08M (68.28 %)
EPS:	TWD0.190

FY	2022
Ingresos:	TWD36.23M
Beneficio Bruto:	TWD32.49M (89.69 %)
EPS:	TWD-0.330

FY	2021
Ingresos:	TWD1.29B
Beneficio Bruto:	TWD1.28B (99.02 %)
EPS:	TWD1.080

Financial Reports:

No articles found.

TaiGen Biopharmaceuticals

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.

Actualizaciones en tiempo real para TaiGen Biopharmaceuticals [4157.TWO]

Upcoming Earnings Alert